Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-105 (Elastin Biosciences)
- Development stage
- Preclinical
- Lead developer
- Elastin Biosciences
- Modality
- Small Molecules
01
Overview
EB-105 is a preclinical-stage small molecule drug candidate being developed by Elastin Biosciences. It is designed to restore tissue structural integrity by boosting the production of elastin and strengthening the elastin-based extracellular matrix. The drug is part of a series of candidates (EB-105 to EB-108) targeting diseases characterized by the loss of or defects in elastin, a critical protein for tissue elasticity. EB-105 is currently under investigation for applications in both cardiovascular diseases and dermatology.
Beyond the preview
Go deeper on EB-105 (Elastin Biosciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-105 (Elastin Biosciences).